8-KFinancial EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Obligation (Nov 15, 2012)

Filed November 15, 2012For Securities:ABT

Summary

This 8-K filing by Abbott Laboratories (ABT) on November 15, 2012, primarily details the financial obligations related to its wholly-owned subsidiary, AbbVie Inc. AbbVie issued a significant amount of senior notes across various maturities and interest rates, totaling $10.5 billion. These notes were issued in a private placement, with a portion exchanged for assets transferred from Abbott to AbbVie in preparation for the upcoming spin-off of AbbVie. Abbott has provided an unsecured, unsubordinated guarantee for these AbbVie notes, which will terminate upon the distribution of AbbVie's common stock to Abbott shareholders. The proceeds from the note issuance will be used by AbbVie to fund a cash distribution to Abbott, and by Abbott to partly finance its ongoing cash tender offers for its own outstanding notes. This transaction is a key financial maneuver in the separation of AbbVie, impacting both entities' debt structures and liquidity.

Key Highlights

  • 1AbbVie Inc. issued $10.5 billion in aggregate principal amount of senior notes across multiple series and maturities (ranging from 2015 to 2042) with fixed and floating interest rates.
  • 2The notes were issued in a private placement to qualified institutional buyers and non-U.S. persons, with a portion exchanged by AbbVie to Abbott for transferred business assets.
  • 3Abbott Laboratories has provided an unsecured, unsubordinated guarantee for all of AbbVie's issued notes.
  • 4The Abbott guarantee for AbbVie's notes will terminate upon the previously announced distribution of AbbVie's common stock to Abbott shareholders.
  • 5Net proceeds from the note issuance (excluding exchanged notes) will be used by AbbVie for a cash distribution to Abbott.
  • 6Abbott plans to use proceeds received from AbbVie to partially fund its cash tender offers for its own outstanding notes.
  • 7A Registration Rights Agreement is in place, requiring AbbVie to file a registration statement for an exchange offer of the notes, with potential for increased interest rates if certain conditions are not met.

Frequently Asked Questions

The main purpose of AbbVie's debt issuance is to raise capital. A significant portion of the proceeds will be used by AbbVie to make a cash distribution to Abbott Laboratories. Abbott, in turn, intends to use these funds to partially finance its cash tender offers for its own outstanding notes. This is a critical financial step in the eventual separation of AbbVie from Abbott.

Abbott Laboratories acts as a guarantor for the notes issued by its subsidiary, AbbVie. This guarantee is unsecured and unsubordinated, meaning Abbott is backing the debt of AbbVie. This guarantee is set to terminate once AbbVie's common stock is distributed to Abbott shareholders, signifying the completion of their separation.

No, the majority of these notes were issued and sold in a private placement to qualified institutional buyers and non-U.S. persons. A portion of the notes were also issued directly by AbbVie to Abbott as consideration for transferred assets, and then subsequently exchanged.

For AbbVie, this issuance adds $10.5 billion in debt to its balance sheet, impacting its leverage ratios. For Abbott, it receives a cash infusion from AbbVie that aids in its debt management strategy (tender offers) and sets up AbbVie as an independent entity with its own capital structure. The guarantee also represents a contingent liability for Abbott until the separation is complete.